Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 600 clinical trials
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

Selinexor (KPT-330, Xpovio) is a first in class selective inhibitor of nuclear export which has been approved for use in relapsed and refractory multiple myeloma (RRMM). This trial will seek to

  • 0 views
  • 25 Mar, 2022
  • 1 location
RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma

RAPA-201-RRMM is an open-label, single-arm, non-randomized multicenter phase II study of RAPA-201 autologous T cells in adults with relapsed, refractory multiple myeloma who have received at

  • 1 views
  • 25 Mar, 2022
  • 1 location
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

This study evaluates the safety and efficacy of novel BCMA-targeted CAR-T cell therapy (CBG-002) for patients with relapsed or refractory multiple myeloma (r/r MM). CBG-002 is designed based on

  • 0 views
  • 15 Apr, 2021
  • 1 location
Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients

medication sparing effects in comparison to standard of care management in Multiple Myeloma subjects.

  • 0 views
  • 24 May, 2022
  • 1 location
Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Evaluate the efficacy and safety of Belantamab Mafodotin, cyclophosphamide, and dexamethasone in patients with Relapsed/Refractory Multiple Myeloma

  • 0 views
  • 22 Mar, 2022
  • 1 location
Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma

with multiple myeloma who have exhausted available treatment options

  • 0 views
  • 23 Mar, 2022
  • 1 location
Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma

populations of CD8+ T cells targeting multiple Myeloma associated antigen peptides in patients with relapsed refractory multiple myeloma (MM). The study will enroll patients with MM who have relapsed

  • 0 views
  • 27 Jan, 2021
  • 4 locations
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

This study is aimed to evaluate the safety, feasibility and efficacy of CAR-T cell therapy in the treatment of relapsed or refractory multiple myeloma

  • 0 views
  • 27 Jan, 2021
  • 1 location
A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma

To determine if KRN125 is non-inferior to filgrastim for the mobilization of hematopoietic stem cells into the peripheral blood in patients with multiple myeloma.

  • 0 views
  • 09 Jun, 2022
  • 21 locations
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant

This phase II trial studies whether daratumumab and hyaluronidase-fihj and pomalidomide work in treating patients with multiple myeloma that has come back (relapsed) after stem cell transplant

tumor cells
neutrophil count
daratumumab
withdrawn
platelet count
  • 2 views
  • 03 Feb, 2022
  • 1 location